Co-Diagnostics, Inc. (NASDAQ: CODX) announced that its Indian joint venture, CoSara Diagnostics Pvt. Ltd., has signed an agreement to expand its commercial and distribution territory across South Asia. The expansion includes Bangladesh, Pakistan, Nepal and Sri Lanka, significantly increasing the company's addressable market to an estimated $13.0 billion. This strategic move positions the molecular diagnostics company for broader deployment of its testing solutions across a region with substantial healthcare needs.
The expansion supports planned commercialization of the CoSara PCR Pro(R) point-of-care platform and SARAGENE(R) product line, subject to regulatory approvals. As the company builds regional distribution channels, this agreement represents a significant step in making molecular diagnostics more accessible across South Asia. The CoSara PCR Pro platform is designed for point-of-care testing, potentially enabling faster diagnosis and treatment decisions in clinical settings throughout the expanded territory.
Co-Diagnostics develops, manufactures and markets state-of-the-art diagnostics technologies that utilize detection and analysis of nucleic acid molecules (DNA or RNA). The company's proprietary technology is also used to design specific tests for its Co-Dx PCR at-home and point-of-care platform, though these products are subject to regulatory review and are not currently for sale. Additional information about the company's technology and products is available at https://co-dx.com/.
The expansion into these four additional South Asian countries represents a substantial market opportunity for Co-Diagnostics and its joint venture partner. With a combined population exceeding 400 million people across Bangladesh, Pakistan, Nepal and Sri Lanka, the potential impact on healthcare delivery could be significant. Molecular diagnostics play a crucial role in infectious disease management, and increased access to these technologies could improve diagnostic capabilities throughout the region.
This announcement follows the company's continued efforts to expand its global footprint and make advanced diagnostic technologies more widely available. The $13 billion estimated addressable market indicates the substantial commercial potential of this expansion, while also highlighting the healthcare needs across South Asia that advanced diagnostics could help address. As regulatory processes proceed in each country, the company will be positioned to bring its molecular diagnostics solutions to healthcare providers and patients throughout the expanded territory.
The full details of the expansion agreement and additional information about Co-Diagnostics' technology platform can be found in the company's official announcement at https://ibn.fm/2aATV. This expansion represents a strategic move in the competitive molecular diagnostics market, potentially positioning Co-Diagnostics for increased market share and broader impact on global healthcare delivery through its joint venture operations in South Asia.
